Trials / Completed
CompletedNCT02220907
Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 52 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teneligliptin/Canagliflozin | Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks. |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2014-08-20
- Last updated
- 2026-01-07
- Results posted
- 2018-08-16
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02220907. Inclusion in this directory is not an endorsement.